BioSpace News Archive

REGENXBIO Inc. announced that initial interim data from a first-in-human single-patient, investigator-initiated trial of RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 disease, a form of Batten disease, were presented at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Jerusalem.

AION Biosystems, a medical technology company dedicated to dramatically expanding the use of remote patient monitoring, has received U.S. Food and Drug Administration 510 clearance of its iTempShield™ device and software system.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.

InflaRx N.V. (Nasdaq: IFRX) announced today that the Company has submitted a Marketing Authorization Application (MAA) for the treatment of adult patients with SARS-CoV-2 induced septic acute respiratory distress syndrome (ARDS) receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) and that the European Medicines Agency (EMA) has validated the MAA.

LifeTech Scientific Corporation announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended 30 June 2023.

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the National Cancer Institute (NCI) has selected the company’s testing laboratory in Phoenix, AZ to participate in the ComboMATCH clinical trials, one of the NCI-funded precision medicine initiatives.

Cleveland Diagnostics, Inc., a leading commercial-stage biotechnology company, is launching its inaugural Prostate Cancer Awareness Campaign this September: ‘A PSA on PSA.’

Recludix Pharma announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at multiple investor conferences in September.

PaxMedica, Inc. (Nasdaq: PXMD) today announced that it will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 – 13, 2023, in New York, NY.

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.